Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A. Tripp
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d191ef95cc404745a8ce8416434d12ad
record_format	dspace
spelling	oai:doaj.org-article:d191ef95cc404745a8ce8416434d12ad2021-12-02T14:58:48ZProbenecid inhibits SARS-CoV-2 replication in vivo and in vitro10.1038/s41598-021-97658-w2045-2322https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad2021-09-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-97658-whttps://doaj.org/toc/2045-2322Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.Jackelyn MurrayRobert J. HoganDavid E. MartinKathy BlahunkaFred D. SancilioRajiv BalyanMark LovernRichard StillRalph A. TrippNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jackelyn Murray Robert J. Hogan David E. Martin Kathy Blahunka Fred D. Sancilio Rajiv Balyan Mark Lovern Richard Still Ralph A. Tripp Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
description	Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.
format	article
author	Jackelyn Murray Robert J. Hogan David E. Martin Kathy Blahunka Fred D. Sancilio Rajiv Balyan Mark Lovern Richard Still Ralph A. Tripp
author_facet	Jackelyn Murray Robert J. Hogan David E. Martin Kathy Blahunka Fred D. Sancilio Rajiv Balyan Mark Lovern Richard Still Ralph A. Tripp
author_sort	Jackelyn Murray
title	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
title_short	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
title_full	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
title_fullStr	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
title_full_unstemmed	Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
title_sort	probenecid inhibits sars-cov-2 replication in vivo and in vitro
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad
work_keys_str_mv	AT jackelynmurray probenecidinhibitssarscov2replicationinvivoandinvitro AT robertjhogan probenecidinhibitssarscov2replicationinvivoandinvitro AT davidemartin probenecidinhibitssarscov2replicationinvivoandinvitro AT kathyblahunka probenecidinhibitssarscov2replicationinvivoandinvitro AT freddsancilio probenecidinhibitssarscov2replicationinvivoandinvitro AT rajivbalyan probenecidinhibitssarscov2replicationinvivoandinvitro AT marklovern probenecidinhibitssarscov2replicationinvivoandinvitro AT richardstill probenecidinhibitssarscov2replicationinvivoandinvitro AT ralphatripp probenecidinhibitssarscov2replicationinvivoandinvitro
_version_	1718389292327239680

Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Ejemplares similares